Evidence map›Paper›PMID 34347216›Full record

Trial reportDocumenta ophthalmologica. Advances in ophthalmology2021

Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study.

Luiza Toscano, Andre Messias, Katharina Messias, Rafaella de Cenço Lopes, Jefferson A Santana Ribeiro, Ingrid U Scott, Rodrigo Jorge

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Documenta ophthalmologica. Advances in ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03904056 (ETDRS Panretinal Photocoagulation), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03904056 nacompletednot on this map

ETDRS Panretinal Photocoagulation (PRP) Combined With Intravitreal Ranibizumab (IVR) Versus Retinal Photocoagulation Targeted to Ischemic Retina Combined With IVR for the Treatment of Proliferative Diabetic Retinopathy

TypeinterventionalSponsorSão Paulo State UniversityRan2014 to 2017Enrolled23ConditionsDiabetic RetinopathyArmsISQ-RP, ETDRS-PRP group
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Luiza ToscanoDepartment of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, SP, Ribeirao Preto, Brazil.
Andre MessiasDepartment of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, SP, Ribeirao Preto, Brazil. amessias@usp.br.ORCID 0000-0002-5328-9608
Katharina MessiasDepartment of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, SP, Ribeirao Preto, Brazil.
Rafaella de Cenço LopesDepartment of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, SP, Ribeirao Preto, Brazil.
Jefferson A Santana RibeiroDepartment of Ophthalmology, School of Medicine, Amazon State University, Manaus, Brazil.
Ingrid U ScottDepartments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
Rodrigo JorgeDepartment of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, SP, Ribeirao Preto, Brazil.
Clinics Hospital of Ribeirão Preto · BRPenn State Milton S. Hershey Medical Center · USUniversidade do Estado do Amazonas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare ETDRS panretinal laser photocoagulation (PRP) combined with intravitreal injection of ranibizumab (IVR) and photocoagulation targeted to ischemic retina (PIR) combined with IVR in patients with proliferative diabetic retinopathy (PDR).

methodsPDR patients were randomly assigned to treatment with either PRP + IVR or PIR + IVR. ETRDS Best-corrected visual acuity (BCVA) and central subfield thickness (CSFT) measured on optic-coherence tomography images (OCT-Heidelberg Spectralis) were recorded at baseline and every 4 weeks for one year. Fluorescein leakage area (FLA) from active new vessels was measured every 12 weeks. Full-field ERG was recorded by means of DTL electrodes, following ISCEV standard recommendations, at baseline and after 3 months.

resultsTwenty-eight eyes completed the study period. At baseline, mean ± SE BCVA (logMAR) was 0.44 ± 0.07 and 0.37 ± 0.08 (P = 0.5030); CSFT (μm) was 324.0 ± 20.4 and 330.1 ± 22.1 (P = 0.8417); and FLA (mm

conclusionsPIR + IVR or PRP + IVR are comparable strategies regarding FLA control in PDR and led to similar retinal function impairment, based on ERG changes up to one-year follow-up. TRIAL REGISTRATION NUMBER: NCT03904056, date of registration 02/11/2019, retrospectively registered.

Indexed as

Diabetes MellitusDiabetic RetinopathyAngiogenesis InhibitorsElectroretinographyHumansIntravitreal InjectionsLaser CoagulationRanibizumabRetinaTomography, Optical CoherenceTreatment OutcomeVisual AcuityAngiogenesis InhibitorsRanibizumabElectroretinographyPhotocoagulationProliferative diabetic retinopathyRanibizumab

Identifiers

PMID34347216
OpenAlexW3192636592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.